Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01373151 · ClinicalTrials.gov registry record · Phase 2
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase 2 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 418
- Enrollment target
NCT01373151 is a Phase 2 study that has completed, run by CSL Behring. The registered enrollment target is 418 participants.
The verdict
NCT01373151, a Phase 2 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 418 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.
Interventions
- DRUG BMS-945429 Placebo
- BIOLOGICAL BMS-945429
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01373151
The ClinicalTrials.gov registry entry for NCT01373151 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-945429 Placebo is the first listed.
NCT01373151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01373151 about?
NCT01373151 is a clinical study titled "Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate". The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.
What is the current status of trial NCT01373151?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 418 participants. The study started on 2011-06. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01373151?
The interventions under investigation include: BMS-945429 Placebo (DRUG), BMS-945429 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01373151?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.